nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—Dactinomycin—sarcoma	0.0227	0.289	CbGbCtD
Amantadine—ABCB1—Mitoxantrone—sarcoma	0.0203	0.259	CbGbCtD
Amantadine—ABCB1—Vincristine—sarcoma	0.014	0.178	CbGbCtD
Amantadine—ABCB1—Etoposide—sarcoma	0.0128	0.163	CbGbCtD
Amantadine—ABCB1—Doxorubicin—sarcoma	0.00873	0.111	CbGbCtD
Amantadine—GRIN3B—testis—sarcoma	0.00625	0.0864	CbGeAlD
Amantadine—DDC—embryo—sarcoma	0.00396	0.0548	CbGeAlD
Amantadine—GRIN2D—tendon—sarcoma	0.00337	0.0466	CbGeAlD
Amantadine—SIGMAR1—mammary gland—sarcoma	0.00312	0.0431	CbGeAlD
Amantadine—GRIN2C—testis—sarcoma	0.003	0.0415	CbGeAlD
Amantadine—GRIN2D—testis—sarcoma	0.00279	0.0386	CbGeAlD
Amantadine—GRIN3A—testis—sarcoma	0.00263	0.0363	CbGeAlD
Amantadine—GRIN2A—tendon—sarcoma	0.00251	0.0346	CbGeAlD
Amantadine—SIGMAR1—myometrium—sarcoma	0.00221	0.0306	CbGeAlD
Amantadine—MAOB—myometrium—sarcoma	0.00212	0.0293	CbGeAlD
Amantadine—GRIN2A—testis—sarcoma	0.00208	0.0287	CbGeAlD
Amantadine—MAOB—embryo—sarcoma	0.00204	0.0282	CbGeAlD
Amantadine—SIGMAR1—seminal vesicle—sarcoma	0.002	0.0277	CbGeAlD
Amantadine—DDC—testis—sarcoma	0.00194	0.0268	CbGeAlD
Amantadine—MAOB—seminal vesicle—sarcoma	0.00192	0.0265	CbGeAlD
Amantadine—Pulmonary oedema—Doxorubicin—sarcoma	0.0019	0.00319	CcSEcCtD
Amantadine—Angiopathy—Etoposide—sarcoma	0.00188	0.00315	CcSEcCtD
Amantadine—Convulsion—Mitoxantrone—sarcoma	0.00188	0.00315	CcSEcCtD
Amantadine—Hypertonia—Doxorubicin—sarcoma	0.00188	0.00315	CcSEcCtD
Amantadine—Hypertension—Mitoxantrone—sarcoma	0.00187	0.00314	CcSEcCtD
Amantadine—Eczema—Epirubicin—sarcoma	0.00187	0.00313	CcSEcCtD
Amantadine—Mediastinal disorder—Etoposide—sarcoma	0.00187	0.00313	CcSEcCtD
Amantadine—Mental disability—Doxorubicin—sarcoma	0.00186	0.00311	CcSEcCtD
Amantadine—Cardiac failure congestive—Epirubicin—sarcoma	0.00185	0.0031	CcSEcCtD
Amantadine—Paraesthesia—Thiotepa—sarcoma	0.00184	0.00309	CcSEcCtD
Amantadine—Anxiety—Mitoxantrone—sarcoma	0.00184	0.00309	CcSEcCtD
Amantadine—DDC—liver—sarcoma	0.00183	0.0253	CbGeAlD
Amantadine—Alopecia—Etoposide—sarcoma	0.00183	0.00307	CcSEcCtD
Amantadine—Somnolence—Thiotepa—sarcoma	0.00182	0.00306	CcSEcCtD
Amantadine—MAOB—hematopoietic system—sarcoma	0.00182	0.0252	CbGeAlD
Amantadine—Renal failure acute—Epirubicin—sarcoma	0.00182	0.00305	CcSEcCtD
Amantadine—Anaphylactic shock—Vincristine—sarcoma	0.00182	0.00305	CcSEcCtD
Amantadine—Oedema—Vincristine—sarcoma	0.00182	0.00305	CcSEcCtD
Amantadine—Dyspepsia—Thiotepa—sarcoma	0.0018	0.00303	CcSEcCtD
Amantadine—Confusional state—Mitoxantrone—sarcoma	0.00178	0.00299	CcSEcCtD
Amantadine—Nervous system disorder—Vincristine—sarcoma	0.00178	0.00299	CcSEcCtD
Amantadine—Decreased appetite—Thiotepa—sarcoma	0.00178	0.00299	CcSEcCtD
Amantadine—Anaphylactic shock—Mitoxantrone—sarcoma	0.00177	0.00297	CcSEcCtD
Amantadine—Oedema—Mitoxantrone—sarcoma	0.00177	0.00297	CcSEcCtD
Amantadine—Gastrointestinal disorder—Thiotepa—sarcoma	0.00177	0.00297	CcSEcCtD
Amantadine—Photosensitivity—Doxorubicin—sarcoma	0.00177	0.00297	CcSEcCtD
Amantadine—Decreased appetite—Dactinomycin—sarcoma	0.00177	0.00297	CcSEcCtD
Amantadine—Fatigue—Thiotepa—sarcoma	0.00177	0.00296	CcSEcCtD
Amantadine—Hyperhidrosis—Vincristine—sarcoma	0.00176	0.00295	CcSEcCtD
Amantadine—Fatigue—Dactinomycin—sarcoma	0.00175	0.00294	CcSEcCtD
Amantadine—MAOB—connective tissue—sarcoma	0.00175	0.0242	CbGeAlD
Amantadine—Constipation—Thiotepa—sarcoma	0.00175	0.00294	CcSEcCtD
Amantadine—Anorexia—Vincristine—sarcoma	0.00173	0.0029	CcSEcCtD
Amantadine—Eczema—Doxorubicin—sarcoma	0.00173	0.0029	CcSEcCtD
Amantadine—Tachycardia—Mitoxantrone—sarcoma	0.00173	0.0029	CcSEcCtD
Amantadine—Cardiac failure—Epirubicin—sarcoma	0.00172	0.00289	CcSEcCtD
Amantadine—Skin disorder—Mitoxantrone—sarcoma	0.00172	0.00288	CcSEcCtD
Amantadine—Lethargy—Epirubicin—sarcoma	0.00171	0.00287	CcSEcCtD
Amantadine—Cardiac failure congestive—Doxorubicin—sarcoma	0.00171	0.00287	CcSEcCtD
Amantadine—Hyperhidrosis—Mitoxantrone—sarcoma	0.00171	0.00287	CcSEcCtD
Amantadine—Hypotension—Vincristine—sarcoma	0.0017	0.00285	CcSEcCtD
Amantadine—Feeling abnormal—Thiotepa—sarcoma	0.00169	0.00283	CcSEcCtD
Amantadine—Anorexia—Mitoxantrone—sarcoma	0.00169	0.00283	CcSEcCtD
Amantadine—Renal failure acute—Doxorubicin—sarcoma	0.00168	0.00282	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—sarcoma	0.00168	0.00282	CcSEcCtD
Amantadine—Feeling abnormal—Dactinomycin—sarcoma	0.00168	0.00281	CcSEcCtD
Amantadine—SIGMAR1—smooth muscle tissue—sarcoma	0.00167	0.0231	CbGeAlD
Amantadine—Hypotension—Mitoxantrone—sarcoma	0.00165	0.00277	CcSEcCtD
Amantadine—Insomnia—Vincristine—sarcoma	0.00164	0.00276	CcSEcCtD
Amantadine—Paraesthesia—Vincristine—sarcoma	0.00163	0.00274	CcSEcCtD
Amantadine—Body temperature increased—Thiotepa—sarcoma	0.00162	0.00272	CcSEcCtD
Amantadine—Leukopenia—Etoposide—sarcoma	0.00161	0.00271	CcSEcCtD
Amantadine—Body temperature increased—Dactinomycin—sarcoma	0.00161	0.0027	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—sarcoma	0.0016	0.00268	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—sarcoma	0.00159	0.00267	CcSEcCtD
Amantadine—Paraesthesia—Mitoxantrone—sarcoma	0.00159	0.00267	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—sarcoma	0.00158	0.00266	CcSEcCtD
Amantadine—Decreased appetite—Vincristine—sarcoma	0.00158	0.00265	CcSEcCtD
Amantadine—Ataxia—Epirubicin—sarcoma	0.00158	0.00265	CcSEcCtD
Amantadine—Dyspnoea—Mitoxantrone—sarcoma	0.00158	0.00265	CcSEcCtD
Amantadine—Somnolence—Mitoxantrone—sarcoma	0.00157	0.00264	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vincristine—sarcoma	0.00157	0.00263	CcSEcCtD
Amantadine—Fatigue—Vincristine—sarcoma	0.00157	0.00263	CcSEcCtD
Amantadine—Convulsion—Etoposide—sarcoma	0.00156	0.00262	CcSEcCtD
Amantadine—Dyspepsia—Mitoxantrone—sarcoma	0.00156	0.00261	CcSEcCtD
Amantadine—Hypertension—Etoposide—sarcoma	0.00156	0.00261	CcSEcCtD
Amantadine—Constipation—Vincristine—sarcoma	0.00155	0.00261	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—sarcoma	0.00155	0.00261	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—sarcoma	0.00155	0.0026	CcSEcCtD
Amantadine—Decreased appetite—Mitoxantrone—sarcoma	0.00154	0.00258	CcSEcCtD
Amantadine—Orthostatic hypotension—Epirubicin—sarcoma	0.00153	0.00257	CcSEcCtD
Amantadine—Fatigue—Mitoxantrone—sarcoma	0.00153	0.00256	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00152	0.00256	CcSEcCtD
Amantadine—Constipation—Mitoxantrone—sarcoma	0.00151	0.00254	CcSEcCtD
Amantadine—Hypersensitivity—Thiotepa—sarcoma	0.00151	0.00253	CcSEcCtD
Amantadine—Hypersensitivity—Dactinomycin—sarcoma	0.0015	0.00251	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—sarcoma	0.00149	0.00589	CbGpPWpGaD
Amantadine—Confusional state—Etoposide—sarcoma	0.00148	0.00249	CcSEcCtD
Amantadine—GRIN2B—EPHB-mediated forward signaling—SRC—sarcoma	0.00148	0.00585	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EZR—sarcoma	0.00148	0.00584	CbGpPWpGaD
Amantadine—Cardiac arrest—Doxorubicin—sarcoma	0.00148	0.00248	CcSEcCtD
Amantadine—Anaphylactic shock—Etoposide—sarcoma	0.00147	0.00247	CcSEcCtD
Amantadine—Asthenia—Thiotepa—sarcoma	0.00147	0.00247	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—sarcoma	0.00146	0.00245	CcSEcCtD
Amantadine—Asthenia—Dactinomycin—sarcoma	0.00146	0.00245	CcSEcCtD
Amantadine—Feeling abnormal—Mitoxantrone—sarcoma	0.00146	0.00245	CcSEcCtD
Amantadine—Dysphagia—Epirubicin—sarcoma	0.00145	0.00243	CcSEcCtD
Amantadine—Pruritus—Thiotepa—sarcoma	0.00145	0.00243	CcSEcCtD
Amantadine—SIGMAR1—cardiac atrium—sarcoma	0.00144	0.02	CbGeAlD
Amantadine—Tachycardia—Etoposide—sarcoma	0.00144	0.00241	CcSEcCtD
Amantadine—SIGMAR1—uterus—sarcoma	0.00144	0.0199	CbGeAlD
Amantadine—Body temperature increased—Vincristine—sarcoma	0.00144	0.00241	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—sarcoma	0.00143	0.00241	CcSEcCtD
Amantadine—Skin disorder—Etoposide—sarcoma	0.00143	0.0024	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—MYOG—sarcoma	0.00143	0.00564	CbGpPWpGaD
Amantadine—Hyperhidrosis—Etoposide—sarcoma	0.00142	0.00239	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—sarcoma	0.00142	0.00238	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—sarcoma	0.00141	0.00557	CbGpPWpGaD
Amantadine—DDC—lymph node—sarcoma	0.00141	0.0194	CbGeAlD
Amantadine—Anorexia—Etoposide—sarcoma	0.0014	0.00235	CcSEcCtD
Amantadine—Diarrhoea—Thiotepa—sarcoma	0.0014	0.00235	CcSEcCtD
Amantadine—Body temperature increased—Mitoxantrone—sarcoma	0.0014	0.00235	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—MYOG—sarcoma	0.00139	0.0055	CbGpPWpGaD
Amantadine—Diarrhoea—Dactinomycin—sarcoma	0.00139	0.00233	CcSEcCtD
Amantadine—MAOB—cardiac atrium—sarcoma	0.00138	0.0191	CbGeAlD
Amantadine—GRIN1—EPH-Ephrin signaling—KDR—sarcoma	0.00138	0.00546	CbGpPWpGaD
Amantadine—Hypotension—Etoposide—sarcoma	0.00138	0.00231	CcSEcCtD
Amantadine—MAOB—uterus—sarcoma	0.00137	0.019	CbGeAlD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—sarcoma	0.00137	0.00543	CbGpPWpGaD
Amantadine—Neutropenia—Epirubicin—sarcoma	0.00136	0.00228	CcSEcCtD
Amantadine—Dizziness—Thiotepa—sarcoma	0.00135	0.00227	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—KDR—sarcoma	0.00135	0.00532	CbGpPWpGaD
Amantadine—Dysphagia—Doxorubicin—sarcoma	0.00134	0.00225	CcSEcCtD
Amantadine—Hypersensitivity—Vincristine—sarcoma	0.00134	0.00225	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—sarcoma	0.00133	0.00525	CbGpPWpGaD
Amantadine—Photosensitivity reaction—Epirubicin—sarcoma	0.00132	0.00222	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—sarcoma	0.00132	0.00523	CbGpPWpGaD
Amantadine—Paraesthesia—Etoposide—sarcoma	0.00132	0.00222	CcSEcCtD
Amantadine—DRD2—Hypothetical Network for Drug Addiction—CREB1—sarcoma	0.00132	0.0052	CbGpPWpGaD
Amantadine—Dyspnoea—Etoposide—sarcoma	0.00131	0.0022	CcSEcCtD
Amantadine—Somnolence—Etoposide—sarcoma	0.00131	0.00219	CcSEcCtD
Amantadine—Hypersensitivity—Mitoxantrone—sarcoma	0.0013	0.00219	CcSEcCtD
Amantadine—Asthenia—Vincristine—sarcoma	0.0013	0.00219	CcSEcCtD
Amantadine—Vomiting—Thiotepa—sarcoma	0.0013	0.00219	CcSEcCtD
Amantadine—Vomiting—Dactinomycin—sarcoma	0.00129	0.00217	CcSEcCtD
Amantadine—Rash—Thiotepa—sarcoma	0.00129	0.00217	CcSEcCtD
Amantadine—Dermatitis—Thiotepa—sarcoma	0.00129	0.00216	CcSEcCtD
Amantadine—Headache—Thiotepa—sarcoma	0.00128	0.00215	CcSEcCtD
Amantadine—Rash—Dactinomycin—sarcoma	0.00128	0.00215	CcSEcCtD
Amantadine—Decreased appetite—Etoposide—sarcoma	0.00128	0.00215	CcSEcCtD
Amantadine—Gastrointestinal disorder—Etoposide—sarcoma	0.00127	0.00213	CcSEcCtD
Amantadine—Asthenia—Mitoxantrone—sarcoma	0.00127	0.00213	CcSEcCtD
Amantadine—Fatigue—Etoposide—sarcoma	0.00127	0.00213	CcSEcCtD
Amantadine—Constipation—Etoposide—sarcoma	0.00126	0.00211	CcSEcCtD
Amantadine—SIGMAR1—tendon—sarcoma	0.00126	0.0174	CbGeAlD
Amantadine—Neutropenia—Doxorubicin—sarcoma	0.00126	0.00211	CcSEcCtD
Amantadine—Diarrhoea—Vincristine—sarcoma	0.00124	0.00209	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—sarcoma	0.00123	0.00486	CbGpPWpGaD
Amantadine—Photosensitivity reaction—Doxorubicin—sarcoma	0.00123	0.00206	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—sarcoma	0.00122	0.00484	CbGpPWpGaD
Amantadine—SIGMAR1—bone marrow—sarcoma	0.00122	0.0168	CbGeAlD
Amantadine—Nausea—Thiotepa—sarcoma	0.00122	0.00204	CcSEcCtD
Amantadine—Feeling abnormal—Etoposide—sarcoma	0.00121	0.00203	CcSEcCtD
Amantadine—Diarrhoea—Mitoxantrone—sarcoma	0.00121	0.00203	CcSEcCtD
Amantadine—Nausea—Dactinomycin—sarcoma	0.00121	0.00203	CcSEcCtD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00121	0.00477	CbGpPWpGaD
Amantadine—Agranulocytosis—Epirubicin—sarcoma	0.00121	0.00202	CcSEcCtD
Amantadine—MAOB—tendon—sarcoma	0.0012	0.0166	CbGeAlD
Amantadine—Dizziness—Vincristine—sarcoma	0.0012	0.00202	CcSEcCtD
Amantadine—Body temperature increased—Etoposide—sarcoma	0.00116	0.00195	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—sarcoma	0.00116	0.00458	CbGpPWpGaD
Amantadine—Vomiting—Vincristine—sarcoma	0.00115	0.00194	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—sarcoma	0.00115	0.00192	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.00115	0.00453	CbGpPWpGaD
Amantadine—Rash—Vincristine—sarcoma	0.00115	0.00192	CcSEcCtD
Amantadine—Dermatitis—Vincristine—sarcoma	0.00114	0.00192	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—sarcoma	0.00114	0.00192	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—sarcoma	0.00114	0.00191	CcSEcCtD
Amantadine—Headache—Vincristine—sarcoma	0.00114	0.00191	CcSEcCtD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—sarcoma	0.00113	0.00447	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—MMP2—sarcoma	0.00113	0.00446	CbGpPWpGaD
Amantadine—Vomiting—Mitoxantrone—sarcoma	0.00112	0.00189	CcSEcCtD
Amantadine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.00112	0.00444	CbGpPWpGaD
Amantadine—Visual impairment—Epirubicin—sarcoma	0.00112	0.00188	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—sarcoma	0.00112	0.00187	CcSEcCtD
Amantadine—Rash—Mitoxantrone—sarcoma	0.00112	0.00187	CcSEcCtD
Amantadine—Dermatitis—Mitoxantrone—sarcoma	0.00111	0.00187	CcSEcCtD
Amantadine—Headache—Mitoxantrone—sarcoma	0.00111	0.00186	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—MMP2—sarcoma	0.0011	0.00434	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—sarcoma	0.00109	0.00432	CbGpPWpGaD
Amantadine—Eye disorder—Epirubicin—sarcoma	0.00109	0.00182	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—sarcoma	0.00108	0.00182	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—EZR—sarcoma	0.00108	0.00428	CbGpPWpGaD
Amantadine—Nausea—Vincristine—sarcoma	0.00108	0.00181	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—sarcoma	0.00108	0.00181	CcSEcCtD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—sarcoma	0.00107	0.00422	CbGpPWpGaD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—sarcoma	0.00107	0.00422	CbGpPWpGaD
Amantadine—SLC22A1—liver—sarcoma	0.00107	0.0147	CbGeAlD
Amantadine—Urinary tract disorder—Doxorubicin—sarcoma	0.00106	0.00178	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—sarcoma	0.00106	0.00178	CcSEcCtD
Amantadine—Asthenia—Etoposide—sarcoma	0.00106	0.00177	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—EZR—sarcoma	0.00106	0.00417	CbGpPWpGaD
Amantadine—Angiopathy—Epirubicin—sarcoma	0.00105	0.00177	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—sarcoma	0.00105	0.00177	CcSEcCtD
Amantadine—Nausea—Mitoxantrone—sarcoma	0.00105	0.00176	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—sarcoma	0.00105	0.00176	CcSEcCtD
Amantadine—SIGMAR1—testis—sarcoma	0.00104	0.0144	CbGeAlD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—sarcoma	0.00104	0.00411	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—sarcoma	0.00104	0.00411	CbGpPWpGaD
Amantadine—Pruritus—Etoposide—sarcoma	0.00104	0.00175	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—sarcoma	0.00104	0.00174	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—sarcoma	0.00104	0.00174	CcSEcCtD
Amantadine—Alopecia—Epirubicin—sarcoma	0.00103	0.00172	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—sarcoma	0.00102	0.00402	CbGpPWpGaD
Amantadine—Mental disorder—Epirubicin—sarcoma	0.00102	0.00171	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—sarcoma	0.00101	0.0017	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—sarcoma	0.00101	0.00399	CbGpPWpGaD
Amantadine—Diarrhoea—Etoposide—sarcoma	0.00101	0.00169	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—sarcoma	0.001	0.00168	CcSEcCtD
Amantadine—MAOB—testis—sarcoma	0.000997	0.0138	CbGeAlD
Amantadine—Cardiac disorder—Doxorubicin—sarcoma	0.000997	0.00167	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—CREB1—sarcoma	0.000995	0.00393	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—sarcoma	0.000993	0.00392	CbGpPWpGaD
Amantadine—Tension—Epirubicin—sarcoma	0.000992	0.00166	CcSEcCtD
Amantadine—SIGMAR1—liver—sarcoma	0.000985	0.0136	CbGeAlD
Amantadine—Nervousness—Epirubicin—sarcoma	0.000982	0.00165	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—sarcoma	0.000975	0.00164	CcSEcCtD
Amantadine—Dizziness—Etoposide—sarcoma	0.000973	0.00163	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—sarcoma	0.000968	0.00162	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—sarcoma	0.00096	0.00161	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—sarcoma	0.000953	0.0016	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—sarcoma	0.000949	0.00159	CcSEcCtD
Amantadine—MAOB—liver—sarcoma	0.000943	0.013	CbGeAlD
Amantadine—Mental disorder—Doxorubicin—sarcoma	0.000941	0.00158	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—CREB1—sarcoma	0.00094	0.00371	CbGpPWpGaD
Amantadine—Vomiting—Etoposide—sarcoma	0.000936	0.00157	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—sarcoma	0.000935	0.00157	CcSEcCtD
Amantadine—Agitation—Epirubicin—sarcoma	0.000929	0.00156	CcSEcCtD
Amantadine—Rash—Etoposide—sarcoma	0.000928	0.00156	CcSEcCtD
Amantadine—Dermatitis—Etoposide—sarcoma	0.000927	0.00156	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—CREB1—sarcoma	0.000925	0.00365	CbGpPWpGaD
Amantadine—GRIN2D—Alzheimers Disease—TP53—sarcoma	0.000923	0.00365	CbGpPWpGaD
Amantadine—Headache—Etoposide—sarcoma	0.000922	0.00155	CcSEcCtD
Amantadine—Tension—Doxorubicin—sarcoma	0.000918	0.00154	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—sarcoma	0.000908	0.00152	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—sarcoma	0.000905	0.00152	CcSEcCtD
Amantadine—GRIN1—Axon guidance—PTPRC—sarcoma	0.000894	0.00353	CbGpPWpGaD
Amantadine—Palpitations—Epirubicin—sarcoma	0.000893	0.0015	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—MYOD1—sarcoma	0.000882	0.00349	CbGpPWpGaD
Amantadine—Vision blurred—Doxorubicin—sarcoma	0.000881	0.00148	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—sarcoma	0.000881	0.00348	CbGpPWpGaD
Amantadine—Convulsion—Epirubicin—sarcoma	0.000876	0.00147	CcSEcCtD
Amantadine—GRIN1—Axon guidance—PLCG1—sarcoma	0.000875	0.00346	CbGpPWpGaD
Amantadine—Nausea—Etoposide—sarcoma	0.000874	0.00147	CcSEcCtD
Amantadine—Hypertension—Epirubicin—sarcoma	0.000873	0.00146	CcSEcCtD
Amantadine—GRIN2B—Axon guidance—PTPRC—sarcoma	0.000871	0.00344	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—CREB1—sarcoma	0.000861	0.0034	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MYOD1—sarcoma	0.00086	0.0034	CbGpPWpGaD
Amantadine—Agitation—Doxorubicin—sarcoma	0.000859	0.00144	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—sarcoma	0.000859	0.00339	CbGpPWpGaD
Amantadine—Anxiety—Epirubicin—sarcoma	0.000857	0.00144	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000855	0.00143	CcSEcCtD
Amantadine—GRIN2B—Axon guidance—PLCG1—sarcoma	0.000853	0.00337	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000852	0.00337	CbGpPWpGaD
Amantadine—DRD2—testis—sarcoma	0.000842	0.0116	CbGeAlD
Amantadine—Dry mouth—Epirubicin—sarcoma	0.000842	0.00141	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—CREB1—sarcoma	0.00084	0.00332	CbGpPWpGaD
Amantadine—Leukopenia—Doxorubicin—sarcoma	0.000837	0.0014	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—sarcoma	0.000836	0.0033	CbGpPWpGaD
Amantadine—Confusional state—Epirubicin—sarcoma	0.000832	0.0014	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—sarcoma	0.000826	0.00139	CcSEcCtD
Amantadine—Oedema—Epirubicin—sarcoma	0.000825	0.00138	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—sarcoma	0.000825	0.00138	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—MDM2—sarcoma	0.000823	0.00325	CbGpPWpGaD
Amantadine—Convulsion—Doxorubicin—sarcoma	0.00081	0.00136	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—sarcoma	0.000809	0.00136	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000808	0.00319	CbGpPWpGaD
Amantadine—Hypertension—Doxorubicin—sarcoma	0.000807	0.00135	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—sarcoma	0.000805	0.00135	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—sarcoma	0.000801	0.00134	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000798	0.00315	CbGpPWpGaD
Amantadine—Hyperhidrosis—Epirubicin—sarcoma	0.000797	0.00134	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—sarcoma	0.000793	0.00133	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000791	0.00133	CcSEcCtD
Amantadine—Anorexia—Epirubicin—sarcoma	0.000786	0.00132	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000785	0.0031	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—SRC—sarcoma	0.000782	0.00309	CbGpPWpGaD
Amantadine—Dry mouth—Doxorubicin—sarcoma	0.000779	0.00131	CcSEcCtD
Amantadine—ABCB1—myometrium—sarcoma	0.000773	0.0107	CbGeAlD
Amantadine—Hypotension—Epirubicin—sarcoma	0.000771	0.00129	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—sarcoma	0.00077	0.00129	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—CREB1—sarcoma	0.000768	0.00303	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—MDM2—sarcoma	0.000765	0.00302	CbGpPWpGaD
Amantadine—Oedema—Doxorubicin—sarcoma	0.000763	0.00128	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—sarcoma	0.000763	0.00128	CcSEcCtD
Amantadine—GRIN2C—Neuronal System—CREB1—sarcoma	0.000762	0.00301	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—SRC—sarcoma	0.000762	0.00301	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—VEGFA—sarcoma	0.000761	0.00301	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—CREB1—sarcoma	0.000759	0.003	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TP53—sarcoma	0.000758	0.00299	CbGpPWpGaD
Amantadine—SIGMAR1—lymph node—sarcoma	0.000755	0.0104	CbGeAlD
Amantadine—Nervous system disorder—Doxorubicin—sarcoma	0.000748	0.00126	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—IL2—sarcoma	0.000747	0.00295	CbGpPWpGaD
Amantadine—Insomnia—Epirubicin—sarcoma	0.000746	0.00125	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—sarcoma	0.000745	0.00125	CcSEcCtD
Amantadine—ABCB1—embryo—sarcoma	0.000744	0.0103	CbGeAlD
Amantadine—GRIN2B—EPH-Ephrin signaling—VEGFA—sarcoma	0.000742	0.00293	CbGpPWpGaD
Amantadine—Skin disorder—Doxorubicin—sarcoma	0.000741	0.00124	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—sarcoma	0.000741	0.00124	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—sarcoma	0.000738	0.00124	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—sarcoma	0.000735	0.00123	CcSEcCtD
Amantadine—Somnolence—Epirubicin—sarcoma	0.000733	0.00123	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—sarcoma	0.000729	0.00288	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CCND1—sarcoma	0.000728	0.00288	CbGpPWpGaD
Amantadine—Anorexia—Doxorubicin—sarcoma	0.000728	0.00122	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—sarcoma	0.000726	0.00122	CcSEcCtD
Amantadine—MAOB—lymph node—sarcoma	0.000723	0.00999	CbGeAlD
Amantadine—Decreased appetite—Epirubicin—sarcoma	0.000717	0.0012	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—sarcoma	0.000713	0.0012	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—sarcoma	0.000712	0.00119	CcSEcCtD
Amantadine—Fatigue—Epirubicin—sarcoma	0.000711	0.00119	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—sarcoma	0.000711	0.00281	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—CREB1—sarcoma	0.000708	0.0028	CbGpPWpGaD
Amantadine—Constipation—Epirubicin—sarcoma	0.000705	0.00118	CcSEcCtD
Amantadine—ABCB1—seminal vesicle—sarcoma	0.000698	0.00965	CbGeAlD
Amantadine—Insomnia—Doxorubicin—sarcoma	0.00069	0.00116	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—sarcoma	0.000685	0.00115	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—sarcoma	0.00068	0.00114	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—sarcoma	0.00068	0.00114	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—sarcoma	0.000679	0.00114	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—JUN—sarcoma	0.000676	0.00267	CbGpPWpGaD
Amantadine—Dyspepsia—Doxorubicin—sarcoma	0.000672	0.00113	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000671	0.00265	CbGpPWpGaD
Amantadine—ABCB1—hematopoietic system—sarcoma	0.000664	0.00918	CbGeAlD
Amantadine—Decreased appetite—Doxorubicin—sarcoma	0.000663	0.00111	CcSEcCtD
Amantadine—GRIN1—Transmission across Chemical Synapses—CREB1—sarcoma	0.000662	0.00262	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—sarcoma	0.000661	0.00261	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000659	0.00111	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—sarcoma	0.000658	0.0011	CcSEcCtD
Amantadine—Constipation—Doxorubicin—sarcoma	0.000653	0.00109	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—sarcoma	0.000652	0.00109	CcSEcCtD
Amantadine—GRIN2B—Transmission across Chemical Synapses—CREB1—sarcoma	0.000646	0.00255	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TP53—sarcoma	0.000644	0.00255	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PTPRC—sarcoma	0.000638	0.00252	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—MDM2—sarcoma	0.00063	0.00249	CbGpPWpGaD
Amantadine—Feeling abnormal—Doxorubicin—sarcoma	0.000629	0.00106	CcSEcCtD
Amantadine—GRIN2A—Transmission across Chemical Synapses—MDM2—sarcoma	0.000628	0.00248	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PLCG1—sarcoma	0.000624	0.00247	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PTPRC—sarcoma	0.000622	0.00246	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—JUN—sarcoma	0.000619	0.00245	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—CTNNB1—sarcoma	0.000615	0.00243	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000609	0.0024	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PLCG1—sarcoma	0.000609	0.0024	CbGpPWpGaD
Amantadine—Hypersensitivity—Epirubicin—sarcoma	0.000608	0.00102	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—JUN—sarcoma	0.000604	0.00239	CbGpPWpGaD
Amantadine—Body temperature increased—Doxorubicin—sarcoma	0.000603	0.00101	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	0.000601	0.00237	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—CTNNB1—sarcoma	0.000599	0.00237	CbGpPWpGaD
Amantadine—Asthenia—Epirubicin—sarcoma	0.000592	0.000993	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000591	0.00233	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—MDM2—sarcoma	0.000586	0.00232	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MYC—sarcoma	0.000584	0.00231	CbGpPWpGaD
Amantadine—Pruritus—Epirubicin—sarcoma	0.000584	0.000979	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—CREB1—sarcoma	0.000582	0.0023	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—JUN—sarcoma	0.000581	0.0023	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000577	0.00228	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—EGFR—sarcoma	0.000571	0.00226	CbGpPWpGaD
Amantadine—Diarrhoea—Epirubicin—sarcoma	0.000564	0.000947	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—sarcoma	0.000562	0.000943	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	0.000558	0.00221	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—SRC—sarcoma	0.000556	0.0022	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—JUN—sarcoma	0.000552	0.00218	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—sarcoma	0.00055	0.00217	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—MDM2—sarcoma	0.000548	0.00216	CbGpPWpGaD
Amantadine—Asthenia—Doxorubicin—sarcoma	0.000548	0.000919	CcSEcCtD
Amantadine—Dizziness—Epirubicin—sarcoma	0.000545	0.000915	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—SRC—sarcoma	0.000542	0.00214	CbGpPWpGaD
Amantadine—Pruritus—Doxorubicin—sarcoma	0.00054	0.000906	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—sarcoma	0.000536	0.00212	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—PDGFRA—sarcoma	0.000536	0.00212	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—MDM2—sarcoma	0.000534	0.00211	CbGpPWpGaD
Amantadine—Vomiting—Epirubicin—sarcoma	0.000524	0.00088	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—sarcoma	0.000522	0.000876	CcSEcCtD
Amantadine—Rash—Epirubicin—sarcoma	0.00052	0.000873	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—sarcoma	0.00052	0.000872	CcSEcCtD
Amantadine—Headache—Epirubicin—sarcoma	0.000517	0.000867	CcSEcCtD
Amantadine—GRIN1—Axon guidance—KDR—sarcoma	0.000513	0.00203	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000508	0.00201	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—CREB1—sarcoma	0.000507	0.002	CbGpPWpGaD
Amantadine—Dizziness—Doxorubicin—sarcoma	0.000505	0.000847	CcSEcCtD
Amantadine—ABCB1—uterus—sarcoma	0.000501	0.00693	CbGeAlD
Amantadine—GRIN2B—Axon guidance—KDR—sarcoma	0.000501	0.00198	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCR4—sarcoma	0.000499	0.00197	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000498	0.00197	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—CREB1—sarcoma	0.000495	0.00195	CbGpPWpGaD
Amantadine—Nausea—Epirubicin—sarcoma	0.00049	0.000822	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—sarcoma	0.000485	0.000814	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—MDM2—sarcoma	0.000481	0.0019	CbGpPWpGaD
Amantadine—Rash—Doxorubicin—sarcoma	0.000481	0.000807	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—sarcoma	0.000481	0.000807	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—TP53—sarcoma	0.00048	0.00189	CbGpPWpGaD
Amantadine—Headache—Doxorubicin—sarcoma	0.000478	0.000802	CcSEcCtD
Amantadine—ABCB1—lymphoid tissue—sarcoma	0.000467	0.00646	CbGeAlD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000463	0.00183	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	0.000459	0.00181	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000457	0.0018	CbGpPWpGaD
Amantadine—Nausea—Doxorubicin—sarcoma	0.000453	0.000761	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—sarcoma	0.000452	0.00178	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—CREB1—sarcoma	0.00045	0.00178	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—FOXO1—sarcoma	0.000443	0.00175	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—CREB1—sarcoma	0.000439	0.00173	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—FOXO1—sarcoma	0.000432	0.00171	CbGpPWpGaD
Amantadine—ABCB1—bone marrow—sarcoma	0.000426	0.00588	CbGeAlD
Amantadine—GRIN1—Neuronal System—MDM2—sarcoma	0.00042	0.00166	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—sarcoma	0.00042	0.00166	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MMP2—sarcoma	0.000419	0.00166	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—MDM2—sarcoma	0.000409	0.00162	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MMP2—sarcoma	0.000409	0.00161	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	0.0004	0.00158	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000396	0.00157	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—sarcoma	0.000391	0.00154	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	0.00039	0.00154	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—sarcoma	0.000381	0.00151	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KDR—sarcoma	0.000366	0.00145	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—sarcoma	0.000364	0.00144	CbGpPWpGaD
Amantadine—ABCB1—testis—sarcoma	0.000364	0.00503	CbGeAlD
Amantadine—GRIN2B—Developmental Biology—KDR—sarcoma	0.000357	0.00141	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—sarcoma	0.000346	0.00137	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—sarcoma	0.000345	0.00136	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—CREB1—sarcoma	0.000344	0.00136	CbGpPWpGaD
Amantadine—ABCB1—liver—sarcoma	0.000344	0.00475	CbGeAlD
Amantadine—DDC—Metabolism—ENO2—sarcoma	0.000341	0.00135	CbGpPWpGaD
Amantadine—DDC—Metabolism—HBA1—sarcoma	0.000338	0.00134	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	0.000335	0.00132	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000328	0.0013	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—sarcoma	0.000322	0.00127	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CREB1—sarcoma	0.000321	0.00127	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—CREB1—sarcoma	0.000321	0.00127	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CREB1—sarcoma	0.000313	0.00124	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—CREB1—sarcoma	0.000303	0.0012	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCR4—sarcoma	0.000302	0.00119	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—sarcoma	0.000301	0.00119	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP2—sarcoma	0.000299	0.00118	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—sarcoma	0.000293	0.00116	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2—sarcoma	0.000292	0.00115	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP2—sarcoma	0.000292	0.00115	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—SRC—sarcoma	0.00029	0.00115	CbGpPWpGaD
Amantadine—DDC—Metabolism—PLCG1—sarcoma	0.000289	0.00114	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000287	0.00113	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO2—sarcoma	0.000287	0.00113	CbGpPWpGaD
Amantadine—MAOB—Metabolism—HBA1—sarcoma	0.000285	0.00113	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—MDM2—sarcoma	0.000285	0.00113	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—SRC—sarcoma	0.000283	0.00112	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VEGFA—sarcoma	0.000283	0.00112	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—sarcoma	0.000279	0.0011	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VEGFA—sarcoma	0.000276	0.00109	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—sarcoma	0.000272	0.00108	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—MDM2—sarcoma	0.000266	0.00105	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000264	0.00104	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—sarcoma	0.000264	0.00104	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—CREB1—sarcoma	0.000264	0.00104	CbGpPWpGaD
Amantadine—ABCB1—lymph node—sarcoma	0.000264	0.00364	CbGeAlD
Amantadine—GRIN1—Axon guidance—EGFR—sarcoma	0.000255	0.00101	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—sarcoma	0.000248	0.000982	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—sarcoma	0.000248	0.00098	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—CREB1—sarcoma	0.000246	0.000971	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PLCG1—sarcoma	0.000243	0.000961	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—sarcoma	0.00024	0.00095	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—sarcoma	0.000234	0.000926	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—sarcoma	0.00023	0.00091	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CTNNB1—sarcoma	0.000229	0.000906	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—sarcoma	0.000225	0.000887	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CTNNB1—sarcoma	0.000224	0.000883	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MDM2—sarcoma	0.000218	0.000862	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—JUN—sarcoma	0.000218	0.00086	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—SRC—sarcoma	0.000207	0.000819	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—sarcoma	0.000204	0.000808	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MDM2—sarcoma	0.000203	0.000804	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—SRC—sarcoma	0.000202	0.000798	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—sarcoma	0.000202	0.000797	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—sarcoma	0.000199	0.000788	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—sarcoma	0.000199	0.000787	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—sarcoma	0.000197	0.000777	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000195	0.000771	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—sarcoma	0.000194	0.000768	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—sarcoma	0.000182	0.000718	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—sarcoma	0.000177	0.0007	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—sarcoma	0.000172	0.000678	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCR4—sarcoma	0.000171	0.000674	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—sarcoma	0.000167	0.000661	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000161	0.000638	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—sarcoma	0.000156	0.000618	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCR4—sarcoma	0.000155	0.000612	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO2—sarcoma	0.000152	0.000601	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HBA1—sarcoma	0.000151	0.000597	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—sarcoma	0.000146	0.000576	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—sarcoma	0.000146	0.000576	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TLE1—sarcoma	0.000144	0.000568	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—sarcoma	0.000144	0.000568	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—sarcoma	0.000142	0.000562	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO2—sarcoma	0.000142	0.00056	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HBA1—sarcoma	0.000141	0.000557	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000141	0.000556	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.00014	0.000554	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000139	0.00055	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PLCG1—sarcoma	0.000129	0.00051	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000126	0.000497	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000123	0.000484	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFC—sarcoma	0.000121	0.000479	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PLCG1—sarcoma	0.00012	0.000475	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—sarcoma	0.00012	0.000473	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000113	0.000446	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—sarcoma	0.000112	0.000441	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.00011	0.000436	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000104	0.000412	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FLT1—sarcoma	9.69e-05	0.000383	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PLCG1—sarcoma	9.53e-05	0.000376	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	9.26e-05	0.000366	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR4—sarcoma	9.15e-05	0.000362	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ATF1—sarcoma	9.05e-05	0.000358	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—sarcoma	8.31e-05	0.000328	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CREB1—sarcoma	8.3e-05	0.000328	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HBA1—sarcoma	8.26e-05	0.000326	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1R—sarcoma	7.1e-05	0.000281	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLCG1—sarcoma	7.05e-05	0.000279	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FOXO1—sarcoma	6.76e-05	0.000267	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—sarcoma	6.76e-05	0.000267	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRB—sarcoma	6.75e-05	0.000267	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRA—sarcoma	6.64e-05	0.000262	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—sarcoma	6.14e-05	0.000242	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KDR—sarcoma	5.59e-05	0.000221	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KIT—sarcoma	5.15e-05	0.000203	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—sarcoma	5.15e-05	0.000203	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREB1—sarcoma	4.9e-05	0.000194	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—sarcoma	4.69e-05	0.000185	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—sarcoma	4.43e-05	0.000175	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—sarcoma	4.06e-05	0.00016	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—sarcoma	3.77e-05	0.000149	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—sarcoma	3.62e-05	0.000143	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—sarcoma	3.53e-05	0.00014	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JUN—sarcoma	3.53e-05	0.000139	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—sarcoma	3.5e-05	0.000138	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SRC—sarcoma	3.16e-05	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—sarcoma	3.08e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—sarcoma	3.04e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—sarcoma	2.83e-05	0.000112	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—sarcoma	2.77e-05	0.00011	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—sarcoma	2.62e-05	0.000103	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—sarcoma	2.33e-05	9.19e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—sarcoma	2.23e-05	8.79e-05	CbGpPWpGaD
